论文部分内容阅读
将 HBV 复制指标阳性的慢性乙型肝炎(慢乙肝)不同治疗的82侧随机分3组:单一药物组:应用抗乙型肝炎免疫核糖核酸;联合药物组:抗乙型肝炎免痰核糖核酸联合口服阿昔洛韦;对照组:肝泰乐。分别治疗慢乙肝井对血清 HBV 进行了对比观察。治疗结束后半年,联合药物组 HBsAg、HBeAg、抗HBc-IgM、HBV-DNA 阴转事分别为26.3%、52.6%、63.6%、64.4%及抗-HBs、抗-HBe 阳转率分别为10.5%、42.1%;单一药物组分别为16.7%、40.5%、48.1%、30.4%及4.8%、33.3%;对照组分别为4.8%、19.0%、0%、0%及0%、14.3%。结果表明:抗乙型肝炎免疫核糖核酸联合阿昔洛韦对清除和抑制HBV 有较明显的效果。
HBV replication-positive chronic hepatitis B (chronic hepatitis B) different treatment of 82 sides were randomly divided into three groups: a single drug group: the application of anti-hepatitis B immune RNA; combined drug group: anti-hepatitis B immune sputum RNA combination Oral acyclovir; control group: liver Tailor. The treatment of chronic hepatitis B wells were compared serum HBV. Six months after the end of treatment, HBeAg, HBeAg, anti-HBc-IgM and HBV-DNA in the combination group were 26.3%, 52.6%, 63.6%, 64.4% and anti-HBs respectively %, 42.1% respectively; the single drug group was 16.7%, 40.5%, 48.1%, 30.4% and 4.8%, 33.3% respectively; the control group was 4.8%, 19.0%, 0%, 0% and 0% and 14.3% respectively. The results showed that the combination of anti-HBV RNA and acyclovir had obvious effects on the clearance and suppression of HBV.